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Abstract.  Immunogold EM was employed to compare 
the distribution of type 1 plasminogen activator inhibi- 
tor (PAId) on the surface of agonist-activated human 
umbilical vein endothelial cells (HUVECs) with that 
of control, unactivated cells. As previously observed, 
(Schleef, R. R., T. J. Podor, E. Durme, J. Mimuro, 
and D. J.  Loskutoff. J.  Cell Biol.  110:155-163), analy- 
sis of cross-sections of nonpermeabilized control 
HUVEC monolayers stained first with affinity-purified 
rabbit antibodies to PAId  and then with gold- 
conjugated goat anti-rabbit IgG, revealed the presence 
of relatively few gold particles (<1-2 % of the total) on 
the apical cell surface.  The majority of gold particles 
were detected primarily in the extracellular matrix be- 
tween the culture substratum and the cell membrane. 
In contrast,  treatment of HUVECs with tumor necro- 
sis factor ot (TNFot; 200 U/ml, 24 h) or with lipo- 
polysaccharide (LPS;  10 #g/ml,  24 h) resulted in an 
increased staining of PAId  not only in the extracellu- 
lar matrix,  but also on the apical cell surface (10-fold 
increase).  Immunoabsorption of the rabbit anti-PAid 
with purified PAId,  or treatment of HUVECs with 
tissue-type plasminogen activator (2.5/zg/ml,  2 h, 
4°C) reduced the amount of staining both on the api- 
cal surface and in the extracellular matrix of agonist- 
activated HUVECs by 80-95 %.  The topographical 
location of PAId on the cell surface was examined 
further by coupling immunogold staining with high 
resolution surface replication.  Transmission  EM of 
surface replicas from TNFo~- or LPS-activated 
HUVECs revealed a general increase in PAId  staining 
both on planar regions and within indentations of the 
apical cell surface.  Nonactivated HUVECs revealed 
PAid-specific immunogold particles only in areas of 
exposed extracellular matrix between the cells and oc- 
casionally at regions of cell-cell contacts.  Analysis of 
activated bovine aortic endothelial cells by immuno- 
electron microscopy, immunologic assays, and flow 
cytometry revealed similar increases in surface PAId. 
These increases in surface PAId could be detected by 
3 h and continued over a 24-h period.  The expression 
of PAId on the luminal  surface of endothelial cells 
during  immune or inflammatory reactions could re- 
duce endothelial fibrinolytic activity, thus,  promoting 
the localized, pathologic formation of intravascular 
thrombi. 
I 
NCREASING  experimental evidence indicates that the sur- 
face of endothelial cells changes dramatically in response 
to inflammatory  stimuli.  For example,  tumor necrosis 
factor ot (TNFa), ~  interleukin  1, and endotoxin (lipopolysac- 
charide [LPS]) cause the appearance of several adhesion mol- 
ecules for leukocytes on the endothelial  surface (Bevilacqua 
et al.,  1989; Johnston  et al.,  1989). In addition,  these com- 
pounds induce the appearance of tissue factor, a protein with 
procoagulant  activity on endothelial  surfaces (Bevilacqua et 
al., 1986a), and decrease the binding and surface activation of 
protein C (Nawroth et al., 1986; Nawroth and Stem, 1986). 
The  latter  effect results  from a  rapid  internalization  and 
degradation  of  cell  surface-associated  thrombomodulin 
(Moore et al.,  1989). 
1. Abbreviations  used in this paper:  BAE, bovine aortic endothelial cell; 
HUVEC, human umbilical vein endothelial cell; LPS, lipopolysaccharide; 
PA, plasminogen activator; PAI, PA inhibitor; TNFc~, tumor necrosis factor 
ct; t-PA, tissue type PA; u-PA, urokinase-like PA. 
Agonist-induced alterations in the hemostatic balance at the 
level of vascular endothelial  cells may also include changes 
in fibrinolytic  components.  For example,  LPS and various 
cytokines stimulate  the production and secretion of type 1 
plasminogen  activator inhibitor (PAl-l)  (Bevilacqua  et al., 
1986b; Colucci et al., 1986; Dubor et al., 1986; Emeis and 
Kooistra, 1986; Nachman et al., 1986; Schleefet al., 1988) 
and decrease tissue-type PA (t-PA) production (Schleef et 
al.,  1988).  These changes  may promote the integrity  and 
maintenance of the fibrin clot. Although four molecules with 
PAl activity have been detected,  PAI-1 appears  to be the 
physiologic  inhibitor  of tissue-type (t-PA) and urokinase- 
type PAs (u-PA) (for review see Sprengers  and Kluft, 1987; 
Loskutoff et al., 1988). It has been shown that t-PA binds to 
cultured human umbilical vein endothelial  cells (HUVECs) 
though a  low- and  a  high-affinity  binding  site.  The high- 
affinity binding  site was identified  as PAI-1 associated with 
the cells (Barnathan  et al., 1988). We have recently demon- 
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HUVECs is present beneath the cells in the extracellular ma- 
a'ix, and that it is this population of PAI-1 that interacts with 
solution phase t-PA (Schleef et al.,  1990).  Little PAL1 was 
detected on the cell surface in these studies of unstimulated 
HUVECs. 
In this report, we employ immunogold EM to demonstrate 
that  TNFot  and  LPS  also  induce  PAId  on the  surface of 
HUVECs and bovine aortic endothelial cells (BAEs).  Fur- 
thermore, we employed indirect fluorescent flow cytometry 
to show that these increases in surface-associated PAI-1 are 
rapid (can be detected within 3 h) and prolonged (still appar- 
ent after 24 h). 
Materials and Methods 
Reagents 
Reagents were obtained as follows: FCS, trypsin, penicillin, and streptomy- 
cin from Gibco Laboratories (Grand Island, NY); medium  199 (M199) 
from M.A. Bioproducts  (Bethesda,  MD); tissue culture plasticware  from 
Coming Glass Works (Coming, NY); endothelial cell growth factor,  Tris 
base, porcine intestinal heparin, purified goat immunoglobulin  (IgG), fibro- 
nectin, glycine, paraformaldehyde,  LPS (E. coli 0Ill:B4), and EDTA from 
Sigma Chemical Co. (St. Louis, MO); cyanogen bromide (CNBr)-activated 
Sepharose 413 from Pharmacia Fine Chemicals (Piscataway, NJ);  10-nM 
gold conjugated-goat anti-rabbit  (Rb) IgG from Janssen Life Sciences Prod- 
ucts (Piscataway, NJ); recombinant TNFc~ (2  x  107 Units/rag)  from Gen- 
zyme Corp. (Boston, MA). 
Fibrinolytic Proteins 
Human PAId was purified from the media conditioned by a transformed hu- 
man lung fibroblast cell line (SV4o WI38 VAI3 2RA) according to proce- 
dures described previously (Hekman and Loskutoff,  1988). Antiserum to 
purified PAL1 was raised in New Zealand Rb according to standard proce- 
dures. Antibodies to PAId were affinity purified using human PAId bound 
to CNBr-activated  Sepharose 4B. Briefly, PAId (500 #g) was coupled to 
3 mi of CNBr-aodvated  Sepharose 4B according to the manufacturer's in- 
structions.  The IgG fraction of Rb antisera to PAId was isolated (schleef 
et ai., 1985) and 100 nag of IgG was circulated (16 h, 4°C) through the PAL 
1-Sepharose column at 10 mi/h. The column was washed with PBS, and then 
eluted with 0.2 M glycine-HC1, pH 2.5. The eluted antibodies were immedi- 
ately neutralized with 1 M Tris-HCl, pH 8.1. Protein concentration was de- 
termined by the method of Bradford (1976). 
Growth and Treatment of  HUVECs 
HUVECs were isolated from two to five freshly collected umbilical cords, 
poo21ed, and grown in culture dishes coated with purified fibronectin (1 #g/ 
cm ). The growth medium consisted of M199 with 20% FCS, and was sup- 
plemented with endothelial cell growth factor (75 #g/ml), porcine intestinal 
heparin (90 #g/mi), and antibiotics (Schleef et al., 1988). For experimental 
use, HUVECs were grown to confluency on either fibronectin-coated  glass 
coverslips (12 mm diameter,  Fisher Scientific Co., Pittsburgh, PA) or fibro- 
nectin-coated 24-well Costar culture plates, and maintained at confluency 
for 3 d before use. To activate HUVECs, the monolayers were washed 3x 
with M199 and incubated for 24 h with growth media supplemented with 
either PBS, 200 U/ml TNF~ or LPS (10 #g/ml). Experiments were per- 
formed with HUVECs cultured between the first and third passage. 
Immunologic Assays and Flow Cytometric Analysis 
for BAE PAI-1 
BAEs were isolated and grown to confluency as described previously  (Mi- 
muro et al., 1987). BAEs were utilized between the tenth and twentieth pas- 
sage. For experimental use, the cells were washed and incubated with 0.1% 
serum-containing media supplemented with or without I0 ng/ml LPS (Saw- 
dey et al.,  1989). The conditioned media (CM) was harvested at the indi- 
cated times and the washed cells were lysed with PBS containing 0.5% Tri- 
ton X-100 by incubation for 10 rain at 220C. Both the CM and the Triton 
X-100-soluble cell lysates were analyzed using a two-site enzyme linked im- 
munoradiometric assay  as  described previously  (Mimuro et al.,  1987; 
Seiffert and Podor,  1991). PAL1 associated with the insoluble ECM was 
analyzed by incubating the plates with an mAb (mAb 12C2) specific for bo- 
vine PAId  (10 #g/ml, 2  h,  37"C) followed by incubation with 125I-goat 
anti-mouse IgG (2  x  105 cpm/nil, 1 h, 37"C). A standard curve of PAI-1 
was prepared by drying overnight known concentrations of purified  PAI-I 
onto 24-well  Costar plates and then processing the plates as described 
above. 
For flow cytometric analysis, BAEs were grown in 60-mm culture dishes, 
and the washed cells were treated for 3, 8, and 24 h in the presence or ab- 
sence of 10 ng/ml LPS.  The cells were  washed  with ice-cold PBS and 
detached by treatment with PBS containing 10 mM EDTA and 0.2 M urea. 
The cells were washed twice by centrifugation at 4°C and the cells were 
incubated (30 min, 4°C) with 10 #g/ml mAb 12C2 anti-PAid followed by 
fluorescein-labeled  goat anti-mouse IgG. The washed cells were analyzed 
using a FACS 440 (Becton-Dickinson & Co., Mountain View, CA) flow 
cytometer.  Fluorochrome was excited with 250 mW of 488 run light using 
a 2 W argon laser. Light emission was detected on a photomultiplier tube 
using a band pass filter (530/30 urn) with 104 cells analyzed over a log 
scale of fluorescent  intensity using the Consort 30 Software data package. 
Cells were gated using forward scatter and side scattered  light to include 
only single endothelial cells in order to exclude both dead or damaged cells 
and aggregated  cells. 
Immunogold Staining Procedure 
HUVEC and BAE monolayers  were washed and fixed in 1.5% parafor- 
maldehyde in M199 for 20 rain at room temperature.  The fixed monolayers 
were washed, incubated for 20 rain with 0.2 M glycine in M199 to neutralize 
residual paraformaldehyde,  and then incubated for 30 rain with 5 #g/ml goat 
IgG in M199 (M199-IgG) to block nonspecific  IgG binding sites. Washed 
HUVEC monolayers were stained for 1 h at room temperature with a pri- 
mary antibody (1 #g/ml of either affinity-purified Rb anti-human PAl-1 or 
normal Rb IgG diluted in M199-IgG),  washed and then stained again with 
10 nM gold-conjugated  goat anti-Rb IgG diluted (1/25) in M199-IgG. BAE 
monolayers were stained with either mAb 12C2 anti-bovine PAL1 or nor- 
mal mouse IgG followed by 5 nM gold-conjugated  goat anti-normai IgG. 
After washing the endothelial monolayers with M199, the cells were stored 
in cold Karnovsky's fixation buffer (1.5  % gluteraidehyde,  2 % paraformaide- 
hyde in 0.1 M cacodylate buffer, pH 7.4) until processed. 
Thin-section EM 
After immunogold staining, monolayers in 24-well costar plates were brief- 
ly rinsed with PBS, postfixed with 1.5% OsO4 in 0.1 M cacodylate buffer, 
pH 7.2, for 1 h at room temperature, and dehydrated  in a graded ethanol 
series. The wells were flat embedded in Epon 812 and after polymerization, 
stained en bloc with uranyl acetate.  To quantify the amount of anti-PAI-I 
specific gold particles bound to the cell surface or culture substratum, four 
strips of 3 x  8 mm from each group were cut out from the Epon sheet con- 
taining cell monolayers.  ~  such strips from the same group were sand- 
wiched together, cells apposed,  with fresh Epon. Sections from these sand- 
wiched blocks bearing two layers of cells were cut perpendicular to the 
culture substratum, double stained with uranyl acetate and lead citrate, and 
mounted on 100-mesh parallel lined grids (Ted Pella, Inc., Tustin, CA) so 
that both cell layers ran longitudinally between two grid bars. Quantification 
of gold particles on nucleated cells was carried out at 15,000x magnifica- 
tion on a  Hitachi  12-UA  electron microscope as  previously described 
(Schleef et al.,  1990).  Briefly, one section from each block was used for 
quantitative analysis and the gold particles associated  with the apical cell 
surface or the ECM were counted in each section over a total of 25 nude- 
ated cells, representing 800-1,000 #M of linear culture substratum surface. 
A total of four blocks, each derived from a separate tissue culture well, were 
examined in a group. The density of gold markers is expressed as the num- 
ber of particles (mean +  SD) per nucleated cell from the four representative 
sections.  Data were statistically  analyzed with a paired t test. 
Surface Replication 
Platinum-carbon replicas of the surface of HUVEC cultures were prepared 
according to the procedure described by Robenek et al. (1984). Fixed and 
imrnunostained monolayers on glass coverslips were deh3xlrated  and critical- 
point dried. The coverslips were mounted on the stage of a Balzers 360 M 
freeze-fracture  apparatus (Balzers Union, Hudson, NH) and the bell jar was 
The Journal of Cell Biology, Volume 113, 1991  1414 Figure 1. Immunoelectron microscopic localization of PAI-I on the surface of control and TNFct-activated HUVECs. HUVEC monolayers 
in 24-well Costar plates were incubated for 24 h in growth media either in the absence (A and B) or presence (C-F) of 200 U/ml TNFct. 
The washed cultures were blocked with M199-IgG, stained with affinity-purified rabbit antibodies to PAI-1 followed by gold-conjugated 
goat anti-rabbit IgG, and then processed for thin-section EM as described in Materials and Methods. (arrowheads) Immunogold particles. 
(A-C, inset)  Low-power magnification of HUVEC with arrow indicating approximate area enlarged in each respective panel. (D) 
magnification of HUVEC with left arrow and right arrow indicating area enlarged in E and F,, respectively. Bars: (A-C, E, and F) 250 
nm;  (D) 2/~m. 
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Particles Associated with Control and Activated HUVECs 
Immunogold particles per cell 
HUVEC  Primary  Apical 
treatment  antibody  surface  ECM 
I. Control  Rb anti-PAI-1  0.44  5:0.50  30.12  5-  11.66 
TNFa  Rb anti-PAI-1  6.36  5-  1.82"  44.06  5-  16.06 
LPS  Rb anti-PAI-1  5.52  5-  1.44"  42.88  5-  12.11 
Control  Nonimmune Rb IgG  0.24  5- 0.43  0.79  5- 0.59 
TNFc~  Nonimmune Rb IgG  0.36  ±  0.43  0.72  5- 0.61 
LPS  Nonimmunue Rb IgG  0.28  5- 0.45  0.85  5- 0.56 
II.  LPS  PBS  +  Rb anti-PAI-I  6.08  5- 2.17  47.28  5-  15.31 
LPS  PAI-1  +  Rb anti-PAI-1  0.40  +  0.51  0.89  5- 0.61 
Confluent HUVEC monolayers were incubated (24 h, 37"C) in growth media 
supplemented  with either PBS, TNFa (200 U/ml) or LPS (10 #g/ml). The cells 
were washed, fixed, and incubated with the indicated primary antibody (1 /zg/ 
ml) followed by gold-conjugated goat anti-Rb IgG. In experiment II, anti- 
PAl-1 (1  #g/ml) were preabsorbed by incubation with a 40-fold excess of 
purified PAI-I. Immunostained  cells were then processed for transmission EM 
as described in Materials and Methods. Data are expressed as the number of 
immunogold particles (mean +  SD per cell) detected on either the apical cell 
surface or associated  with the ECM and were derived by analyzing 25 nucleat- 
ed cells/section (four section/group). 
* p < 0.001 compared to control. 
Table II. Effect of  t-PA on the Presence 
of  PAl-1-specific Immunogold Particles Associated 
with TNFa-activated  HUVECs 
Immunogold particles per cell 
HUVEC  Primary  Apical 
treatment  antibody  surface  ECM 
-  t-PA (0 h)  Rb anti-PAI-1  7.04  5- 2.40  52.48  5- 23.43 
-  t-PA (2 h)  Rb anti-PAI-1  6.88  +  2.26  51.48  +  21.25 
+  t-PA (2 h)  Rb anti-PAI-1  1.00  5- 0.41"  13.88  5- 6.24* 
-  t-PA (0 h)  Normal Rb IgG  0.52  5- 0.50  0.80  5- 0.50 
-  t-PA (2 h)  Normal Rb IgG  0.40  5- 0.51  0.85  ±  0.59 
+  t-PA (2 h)  Normal Rb IgG  0.48  5- 0.51  0.93  5- 0.62 
Confluent HUVEC monolayers were treated with 200 U/nil TNFct for 24 h, 
washed, and incubated (4°C) in M199 in the presence or absence of 2.5 ~g/trd 
t-PA. At the indicated times the cells were washed and immunostained for 
PAI-1 as described in the legend to Table I. Data shown were from four sec- 
tions/group in which the number of gold particles associated  with 25 nucleated 
cells/section were determined. Data are expressed as the number of immuno- 
gold particles (mean +  SD per cell) detected on either the apical cell surface 
or associated  with the ECM and were derived by analyzing 25 nucleated  cells/ 
section (four sections/group). 
* p < 0.005 compared to control. 
evacuated.  Replicas  were  obtained  by  shadowing the cell  surface  with 
platinum-carbon at an angle of 38 °, followed by carbon at 90  °. The replicas 
were cleaned overnight in household bleach and washed in distilled water. 
They were picked up on 200 mesh copper grids and examined in a Hitachi 
12-UA electron microscope. 
Results 
Immunoelectron Microscopic Localization of  PAil on 
the Surface of Control and Activated HUVECs 
Immunoelectron microscopy was employed to determine  if 
agonist-induced activation  of HUVECs alters the distribu- 
tion of PAId.  As previously observed by  electron  micro- 
scopic examination (Schleef et al., 1990), staining of control 
HUVEC monolayers first with antibodies  to PAId and then 
with  10-nm gold-conjugated goat anti-Rb IgG revealed the 
presence of P/d-l-specific gold particles  primarily between 
the culture substratum and the cell membrane (Fig. 1, A and 
B). Staining in the ECM was especially prominent at the pe- 
riphery or edges of each cell, possibly because of the inabil- 
ity of the antibodies to evenly penetrate  beneath the fixed 
cells.  The apical cell surface of control HUVECs was rela- 
tively devoid of PAI-1 with an occasional gold particle being 
detected every two or three cells. In contrast to these results, 
when HUVECs  were activated  by treatment  with TNFot, 
gold particles could be detected not only in the ECM but also 
on the apical surface of  all cells (Fig. 1, C-F). Gold particles 
on  the  apical  surface of TNFot-activated HUVECs  were 
present either as widely dispersed single gold particles (E), 
or in isolated clusters adhering to fibrous material (Cand F). 
Heat treatment (100°C,  10 rain) of the cytokine preparations 
were found to prevent not only the cytokine-mediated in- 
crease in PAI-1 production (Bevilacqua et al., 1986b; Schleef 
et al., 1988),  but also the increase in P/d-1 associated with 
apical cell surfaces (data not shown), suggesting that these 
responses  were not mediated by LPS in the recombinant 
preparations. However,  LPS treatment of HUVECs also in- 
creased the amount of gold particles present on the apical 
surface of cells stained with antibodies to PAI-1 (Fig. 2). As 
observed with TNFog gold particles were present either in 
clusters (A),  as doublets (B and C), or as singletons (D). 
Quantitation of the total number of particles distributed over 
25  nucleated cell lengths (,~800-1,000  #M linear length) 
demonstrated a ,x,10-fold increase in the amount of gold par- 
ticles detected on the dorsal surfaces of the TNF- and LPS- 
activated cells compared to the untreated control cells (Table 
I). Pre-absorption of  the antibodies with an excess of  purified 
PAId reduced the number of gold particles on the cell sur- 
face and ECM by over 90%  (Table I). 
Although PAI-1 is synthesized as an active molecule, it is 
relatively unstable in solution and rapidly decays into a latent, 
inactive form at 37°C (Levin, 1986; Kooistra et al., 1986). 
Localization of PAI-1 on the  surface of endothelial cells 
Figure 2. Effect of LPS on the distribution of PAI-1 on the apical cell surfaces of cultured HUVECs. HUVEC monolayers in 24-well Costar 
plates were incubated for 24 h  in growth media supplemented with 10/zg/ml LPS. The washed cultures were blocked with M199-IgG, 
stained with afffinity-purified  rabbit antibodies to PAId followed by gold-conjugated  goat anti-rabbit IgG, and then processed for thin-section 
EM as described in Materials and Methods. A-D show examples of cells processed as above. (arrowheads)  Immunogold particles. (A, 
inset) Low magnification of HUVEC with open arrow and closed arrow indicating approximate area enlarged in A and B, respectively. 
(C, inset) Low-power  magnification of HUVEC with arrow indicating area enlarged in C. (D) Gold particles associated with an invagination 
of the surface of an LPS-stimulated HUVEC. Bars, 250 nm. 
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hibitor was in an active conformation and capable of inter- 
acting with PAs. We assessed the activity of surface-bound 
PAI-1 by determining whether it reacted with exogenously 
added t-PA. Solution-phase t-PA reduced the concentration 
of PAI-1 in the ECM of TNFa-activated HUVECs (Table II), 
consistent with previous results for nonactivated HUVECs 
(Schleef et al.,  1990). The addition of exogenous t-PA also 
reduced the amount of PAl-l-specific gold particles detected 
on the apical cell surface of TNFo~-activated  HUVECs by 
over 80% (Table II). Again, HUVECs stained with nonim- 
mune IgG as the primary antibody exhibited low gold stain- 
ing on both the apical and the ECM (Table II). 
Surface Replicas 
Drying of cultured fibroblasts (Robenek et al.,  1983), mac- 
rophages (Robenek et al.,  1984) and platelets (Isenberg et 
al.,  1987) using the critical point method with the subse- 
quent preparation of surface replicas has permitted the visu- 
alization of a number of cell surface proteins over extended 
areas of plasma membrane surfaces using the transmission 
electron microscope. To determine whether activation of en- 
dothelial cells might cause changes in the surface distribu- 
tion of PAI-1 not appreciated in conventional thin sections, 
we studied surface replicas of immunostained unstimulated 
and TNFct-stimulated endothelial cells. Examination of the 
apical cell surface of control HUVECs by this technique re- 
vealed the presence of numerous invaginations in an other- 
wise smooth cell surface (Fig. 3). Control HUVECs immu- 
nostained for PAI-1 contained low quantities of  gold particles 
on the apical cell surface (Fig. 3, B and D). However, in areas 
between two ceils where the ECM was exposed, as well as 
on the edges of the cell in the vicinity of the ECM, PAl-I- 
specific immunogold particles were readily detected bound 
to the ECM (Fig.  3 C). 
Stolpen et al. (1986) reported that TNFo~ treatment disrupts 
the  normal cobblestone morphology of HUVECs,  result- 
ing in a more fibroblastic-like appearance. TNFa-activated 
HUVECs possessed more cytoplasmic extensions and an in- 
crease in the intercellular spaces (Fig.  4, A and D),  thus 
confirming this observation. Again, PAl-l-specific gold par- 
ticles were readily detected in the ECM exposed between ad- 
jacent HUVECs (Fig. 4 B). However, the amount of PAl-I- 
specific gold particles on the cell's apical surfaces was also 
dramatically increased (Fig. 4, B and C). PAI-1 was present 
both on planar regions of the cell surface (Fig. 4 B) and in 
invaginations of the cell's membrane (Fig. 4  C),  and both 
singletons and clusters of two to three gold particles were 
routinely detected. Gold particles were rarely detected either 
on the ECM or the cell surface of TNFct-activated HUVECs 
stained with nonimmune IgG (Fig. 4 D). 
Association of PAI-1 with the Surfaces 
of  LPS-activated BAEs 
To demonstrate that the association of PAI-1 with the surface 
of activated-endothelial cells is not unique to HUVECs, we 
also have investigated changes in the distribution of PAI-1 in 
BAEs  after their  treatment  with  LPS.  In  comparison  to 
HUVECs, a 1,000-fold lower concentration of LPS was uti- 
lized in experiments with BAEs, as higher concentrations 
were cytotoxic as shown by trypan blue exclusion and by flow 
cytometry studies. Thin-section electron microscopic exam- 
ination of these cells revealed a pattern of PAl-1 on the surfaces 
of LPS-activated BAEs (data not shown) that was similar to 
that described above for activated HUVECs.  Immunologic 
assays indicated that the increases in PAI-1 associated with 
BAEs could be detected in the Triton X-100-soluble cell ex- 
tract and in the ECM within 4 h after exposure to LPS and 
remained elevated for at least 24 h (Fig. 5, B and C). To in- 
vestigate the kinetics of the LPS-induced increases in the 
surface expression of PAI-1 in more detail, we immunofluo- 
rescently stained control and activated BAEs for cell surface 
PAl-1 after 3, 8, and 24 h exposure to LPS, and then analyzed 
the cells by flow cytometry. A slight shift to the right in the 
fluorescent labeling intensity could be detected within 3 h 
using this procedure (Fig. 6 A). The fluorescent labeling in- 
tensity continued to shift to the right over the 24-h treatment 
period (B and C), indicating further increases in PAl-1 asso- 
ciated with the cell surface. All cells seemed to have PAI-1 
on the cell surface since only a single, rather homogeneous 
population of cells were detected after 24 h, and these were 
well displaced from the untreated control cells. 
Discussion 
Research over the past few years has revealed that key sur- 
face-related functions of the vascular endothelium appear to 
be dynamically modulated (for review see Gimbrone, 1986). 
For example, the adhesivity of leukocytes and tumor cells 
to endothelial cells is dependent on endothelial surface mol- 
ecules which are inducible by a  number of physiological 
stimuli  (e.g.,  LPS, TNFot,  etc.;  Bevilacqua et al.,  1989). 
Alteration in surface thrombogenic properties include the 
rapid induction of tissue factor on the cell surface and the 
concomitant depression of  cell surface antithrombotic activi- 
ties (Nawroth et al., 1986; Nawroth and Stem, 1986). In this 
report,  we provide data  which  indicate that the dynamic 
changes in the cell surface properties of cultured endothelial 
cells extend to the expression of PAl-1. 
Thin-section transmission EM was employed to demon- 
strate that the concentration of PAI-1 was increased ~10-fold 
on  the  apical  surface  of agonist-activated  HUVECs  and 
BAEs (Figs.  1 and 2; Table 1). Flow cytometric analysis of 
Figure 3.  Surface replicas of control HUVECs immunostained for PAl-1. Control HUVEC monolayers were fixed and stained with Rb 
anti-PAI-1 followed by gold-conjugated goat anti-Rb IgG. Surface replicas of the immunostained ceils were prepared as described in 
Materials and Methods and examined in the transmission electron microscope. (A) Low-power  magnification (7,000  x) of a cell contact area 
between two HUVECs. The open arrow represents the area shown in B at higher magnification (42,000×).  The closed arrow represents an 
area of exposed ECM between two ceils that is shown in C at higher magnification (42,000x). The closed double arrow represents an 
area of the apical cell surface shown in D at higher magnification (42,000 x). (arrowheads)  Gold particles. Bars: (A) 1/zm; (B-D) 250 rim. 
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Figure 5. Effect of LPS on the 
distribution of PAIl associated 
with BAEs. BAEs in 24-well 
Costar plates were incubated 
in the presence (solid symbols) 
or absence (open symbols) of 
10 ng/ml LPS. At the indicated 
times,  the CM (,4) were  har- 
vested and the washed monc~ 
layers were extracted  with  PBS 
containing 0.5 % Triton X-IO0. 
The  cell  extracts  (CE)  (B) 
were collected and the culture 
plates were washed twice with 
distilled water. The PAI-1 con- 
centration in the CM, CE, or 
the ECM remaining associated 
with  the  culture  plates  (C) 
was quantitated  immunologi- 
cally as described in Materials 
and  Methods.  Data  are  ex- 
pressed  as mean +  SD from 
quadruplicate  wells. 
LPS-activated BAEs confirmed these results and indicated 
that the surface expression of PAI-1  increased over a 24-h 
period (Fig. 6). In contrast to the LPS-treated BAEs, control 
BAEs exhibited a slight decrease in cell surface PAL1 stain- 
ing over the 24-h period (Fig.  6).  This decrease may have 
resulted from the relative decline in the rate of PAL1  pro- 
duction caused by reducing the serum concentration in this 
system (Sawdey et al.,  1986,  1989).  Evidence that the anti- 
bodies were actually detecting changes in the surface distri- 
bution of PAI-1 was provided by the >95 % reduction in the 
concentration of gold particles associated with the cell sur- 
faces after immunoabsorption of the antibody preparations 
with purified PAL1 (Table I), or upon treatment of the cells 
with  t-PA  (Table  II).  Moreover,  we  could  detect  similar 
changes in PAI-1 on surfaces of activated BAEs using mAbs 
specific for bovine PAI-1  (Fig.  6). 
Thin-section immunoelectron microscopic analysis reveals 
only small amounts of the cell's membrane and does not readi- 
ly permit the visualization of PAI-1 molecules and cell sur- 
face structures on either side of a particular section. There- 
fore, to investigate the topographical distribution of PAI-1 on 
the surface of control and agonist-activated HUVECs in more 
detail, we prepared platinum-carbon surface replicas of our 
immunogold-labeled HUVECs (Figs.  3 and 4).  This tech- 
nique is readily applicable to immunogold staining since the 
gold particles are resistant to digestion with sodium hypo- 
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Figure  6.  Flow  cytometric 
analysis  for PAL1 associated 
with control and LPS-activated 
BAEs.  BAEs in  60-mm  di- 
ameter plates were incubated 
in the presence (solid symbols) 
or absence (open symbols) of 
10 ng/ml LPS. Duplicate BAE 
cultures  were harvested  after 
incubation for either 3 h (A), 
8 h (B), or 24 h (C), and the 
cell  surfaces  were  analyzed 
immunological.ly for PAI-1 by 
FACS as described in Materials 
and Methods.  Representative 
profiles are shown after sub- 
straction  of background  ob- 
tained with an irrelevant mAb. 
appear as circular black dots (i.e., 10 nM in diameter) in the 
surface replicas. Examination of replicas of immunostained 
control HUVECs in the transmission electron microscope 
(Fig.  3) confirmed our observation that PAL1  was present 
only at low amounts  on their apical cell  surface.  Surface 
replicas  of agonist-activated  HUVECs  (Fig.  4)  not  only 
confirmed the observation that PAL1 was increased, but also 
revealed that it was increased throughout the cell surface, 
both on planar areas of the cell membrane and within invagi- 
nations of the cell surface. Indentations in surface replicas 
of human skin fibroblasts (Robenek et al.,  1983) and mouse 
peritoneal macrophages (Robenek et al.,  1984)  have been 
reported  to  localize  gold-conjugated  native  and  modified 
LDL, and are believed to represent endocytotic structures 
(i.e., coated pits) in the cell membranes of these two types 
of cells. On the other hand, the ability of t-PA to reduce the 
concentration of PAI-1 associated with HUVECs suggests the 
possibility that PAL1 is in the active conformation on the api- 
cal cell surface of HUVECs, a hypothesis that is consistent 
with the known biochemical properties of active PAI-1 when 
bound to a stabilizing protein (Loskutoff et al.,  1988). One 
protein presently identified as capable of both binding and 
stabilizing this inhibitor in an active form is the adhesive gly- 
coprotein, vitronectin. PAI-1 bound to immobilized (Mimuro 
et al.,  1987;  Mimuro and Loskutoff, 1989) or soluble (De- 
Figure 4. Surface replicas of TNFc~-activated HUVECs immunostained for PAI-1. Confluent HUVEC monolayers were incubated (24 h, 
37°C) in growth media supplemented with 200 U/ml TNFc~. The cells were washed, fixed, and stained with Rb anti-PAL1 (A-C) or nonim- 
mune IgG (D) followed by 10-nm gold-conjugated goat anti-Rb IgG. Surface replicas of the immunostained cells were prepared as described 
in Materials and Methods and examined in the transmission electron microscope. (A) Low magnification (7,000x) or a cell contact area 
between two TNFcc-activated HUVECs stained with Rb anti-PAI-1. The open arrow represents an area of exposed ECM between the two 
cells that is shown at higher magnification (42,000x)  in B. The closed arrow represents  the area shown in C at higher magnification 
(42,000x). (D) Cell contact area between two TNFc~-activated  cells stained with nonimmune IgG. (inset) Low magnification with double 
arrow indicating area shown in D at higher magnification (42,000x).  (arrowheads) Gold particles.  Bars: (.4 and D, inset) 1 #m; (B-D) 
250 nm. 
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idly interacts with t-PA, and the resulting t-PA/PAI-1 com- 
plexes  dissociate  from the vitronectin  surface.  Since both 
LPS and TNFot cause morphological  rearrangement of the 
monolayer, it is also possible that some of the cell surface 
PAl-1 located at the periphery may originate from the ECM 
and be relocated to apical cell surfaces during the rearrange- 
ment of the cells. Further experiments will be necessary to 
define the role of vitronectin  and/or other proteins  in the 
binding of PAId to endothelial ceils, and to establish the im- 
portance of these membrane invaginations in the expression 
of endothelial-associated  PAl-1. 
The interaction of t-PA with endothelial cells has previ- 
ously been studied by several laboratories utilizing nonacti- 
vated HUVECs (Hajjar et al., 1987; Barnathan et al., 1988; 
Sakata et al.,  1988).  These reports have led to the concept 
that t-PA interacts with endothelial cells through high-affinity 
and low-affinity binding sites (Hajjar et al., 1987; Barnathan 
et al., 1988).  Although the dissociation constants and num- 
ber of binding  sites  for these  endothelial  t-PA "receptors" 
varies from laboratory to laboratory, the high-affinity bind- 
ing site for t-PA appears to be PAId (Barnathan et al., 1988). 
The data reported here indicate that PAI-1 associated  with 
the  ECM  and cell surfaces  of both  control  and activated 
HUVECs  is accessible to soluble  t-PA. Since  compounds 
present in different serum lots have been found to alter the 
production  of PAId  in  endothelial  ceils  (Sawdey et  al., 
1986),  one possibility  that would account for the reported 
discrepancies in the t-PA binding data may be the altered sur- 
face expression of PAl-1 induced by these compounds which 
may be present at varying degrees  in the different serum 
preparations. The accessibility of the ECM-associated PAl-1 
to t-PA may be caused by the absence of tight junctions be- 
tween the endothelial cells when they are grown on plastic 
surfaces (Schleef et al.,  1990). 
In summary, we have demonstrated that TNFc~ and LPS 
can act on cultured endothelial cells to increase the expres- 
sion of PAl-1 on the apical cell surface. In vivo, these actions 
could lead to the development and maintenance of intravas- 
cular and perivascular fibrin in a variety of pathophysiologi- 
cal settings, thereby influencing the evolution of thrombotic 
and inflammatory processes.  Additional experiments will be 
required to delineate the location, concentration, and role of 
PAId  associated  with both unstimulated and agonist-acti- 
vated endothelial  cells in vivo. 
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